Related Experiment Videos
Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer
1Johns Hopkins Oncology Center, Johns Hopkins School of Medicine, Baltimore, MD 21231-001, USA.
The Cancer Journal From Scientific American
|June 10, 1998
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer.
bioRxiv : the preprint server for biology·2024
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
Prostate cancer and prostatic diseases·2016
The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.
Prostate cancer and prostatic diseases·2013
Effect of concurrent intra-arterial infusion of platinum drugs for patients with stage III or IV uterine cervical cancer treated with radical radiation therapy.
The cancer journal from Scientific American·2000
Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586).
The cancer journal from Scientific American·2000
Negative margin status improves local control in conservatively managed breast cancer patients.
The cancer journal from Scientific American·2000
The value of postlumpectomy mammogram in the management of breast cancer patients presenting with suspiciouis microcalcifications.
The cancer journal from Scientific American·2000
Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia.
The cancer journal from Scientific American·2000
Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
The cancer journal from Scientific American·2000
Targeting Cancer-Associated Fibroblasts with Small-Molecule Inhibitors: Molecular Mechanisms and Therapeutic Potential.
Drug design, development and therapy·2026
EGFR-antibody-decorated cancer-cell-membrane-coated MOF nanoplatform enables targeted delivery of the STING agonist diABZI for pancreatic cancer immunotherapy.
International journal of pharmaceutics: X·2026
Targeting MAT2A-S-adenosylmethionine (SAM) Axis Attenuates DNA Damage Response and Cancer Stemness to Increase Platinum Sensitivity in Ovarian Cancer.
bioRxiv : the preprint server for biology·2026